[ad_1]
New York, Aug 31, 2020 (GLOBE NEWSWIRE) – Reportlinker.com Announces Release of Report “COVID-19 Vaccines – Big Pharma and Biotech Race to Make Vaccines Available by End of 2020” – https: // www .reportlinker.com / p05953329 /? utm_source = GNW
The recession is imminent for the world economy. However, some hope has emerged as a handful of research institutions and pharmaceutical corporations and regulatory authorities accelerate their efforts to provide a vaccine for the novel coronavirus. It is important to track the progression of these potential vaccines, as it provides a rough indication of when locks can be lifted more safely and social distancing can be relaxed, allowing businesses to operate as usual without fear. for public health.
Key points
– AstraZeneca has formed a partnership with the University of Oxford to assist in the development, manufacture, commercialization and distribution of a potential COVID-19 vaccine. The company plans to supply 2 billion doses through 2020 and 2021 and has established a strong manufacturing and distribution network in collaboration with several global organizations to help the company achieve its goals effectively. In terms of vaccine development, the Oxford University candidate is one of the most advanced and has reported strong efficacy and safety results from the results of its phase I / II clinical trials in the UK on 20 July. . The group is now focused on phase III trials in Brazil. and South Africa to demonstrate that the vaccine can cause immunity in large populations safely and effectively. If successful, AstraZeneca will be the world’s leading supplier of COVID-19 vaccines
– Chinese vaccine maker Sinovac is also close to obtaining regulatory approval for its own COVID-19 vaccine. The company has also started phase III clinical trials in Brazil and has reported positive results from previous clinical trials completed in a small population of 743 healthy volunteers, ages 18 to 59. ‘ Although the company is optimistic about its ability to produce a valid COVID-19 vaccine, there are concerns about the group’s production and distribution capabilities. If its vaccine candidate is approved, the company will have a difficult time meeting global demand for vaccines. Government support will help Sinovac increase its manufacturing capabilities, but production will remain well below AstraZeneca’s production estimates.
– The BCG vaccine, traditionally used to prevent tuberculosis, is the only other vaccine that will undergo phase III clinical trials for COVID-19 in July 2020. However, the trials will only test the ability of vaccines to produce a non-specific immune response and whether this will help weaken the severity of the virus. The research could benefit key workers, who are at increased risk of infection, by increasing their tolerability until a specific vaccine is available. Vaccines in less advanced stages of development offer an alternative to vaccines currently undergoing phase III testing. If phase III trials do not demonstrate that the vaccine is efficient and safe enough for use globally, the vaccines being developed by companies such as BioNTech, Valneva, Moderno, CanSino, and the Wuhan Institute of Biological Products will become the best. most promising candidates.
Scope
– Examine the race to get a new vaccine.
– See who the leaders are and what possible companies and groups are managing them
– Examine production plans and compare approaches.
Reasons to buy
– What vaccine groups are ahead in the race to produce a vaccine?
– How many are likely to achieve their goal?
– Who has the biggest production plans?
– What different approaches are being taken?
Read the full report: https://www.reportlinker.com/p05953329/?utm_source=GNW
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you can get all the market research you need, instantly, in one place.
__________________________
Clare: [email protected] US: (339)-368-6001 Intl: +1 339-368-6001
